Weight Management

A daily dose of clinical news on Patient Care you may have missed.

ESC Congress 2023. The results of STEP-HFpEF could "change the nature of the conversation about the role of obesity in HFpEF," said PI Mikhail Kosiborod, MD.

More than 90 million adults in the US with overweight/obesity are candidates for weight loss treatment with semaglutide 2.4 mg, according to a new study.

Most Americans are aware of the hot prescription drugs associated with weight loss and many are interested in using them. But access and administration are problematic.

In adults with obesity or overweight plus comorbidities but without T2D once-weekly tirzepatide was associated with significant and durable weight loss vs placebo.

Methods proven to prevent ASCVD may fall short in certain populations if the impacts of SDOH are not closely monitored. The ACC/AHA provide considerations for 7 health domains.

Your daily dose of clinical news you may have missed.

Is BMI or body fat a better estimate of obesity?; spoiler: older women do drink ETOH; USPSTF vs ACC/AHA; plus no more opioids for LBP and a primer on migraine meds.

In Israel, where 60% of adults are overweight, new research prompts investigators to suggest that % body fat should replace BMI as the gold standard measure of obesity.

Underestimation of weight status increased while overestimation decreased during the last 2 decades, according to results from a study of over 745 000 adolescents.

Retatrutide, survodutide, orforglipron. The 3 new GLP-1 agonist-based AOMs showed weight loss of up to 20% and are well worth watching.

ADA 2023: Weight loss with the combination GLP-1/GIP/glucagon receptor agonist was as high as 30% in study participants who received the highest dose.

Your daily dose of clinical news you may have missed.

ADA 2023. Once-daily oral semaglutide 50 mg induced 15.1% weight loss in adults with overweight or obesity without type 2 diabetes vs placebo.

Your daily dose of clinical news you may have missed.

ADA 2023: The investigational oral GLP-1 RA resulted in weight loss comparable to injectable GLP-1 RA formulations and requires no food or water restrictions.

ADA 2023: Among survodutide-treated participants in a phase 2 study, more than half lost more than 50% of baseline bodyweight, reported PI Carel le Roux, MBChB, PhD.

ADA 2023: SURMOUNT-2 findings show tirzepatide is associated with greater weight loss in adults with T2D than any other treatment studied to date.

Type 2 diabetes will continue to comprise more than 90% of this population and obesity will be the primary driver, according to Global Burden of Disease researchers.

ADA 2023. Retatrutide, an investigational triple GLP-1/GIP/glucagon agonist, may provide benefits in liver fibrosis and obesity as well as in glycemic control.

ENDO 2023. The pattern of intermittent fasting improved glycemic measures in a weight-independent fashion after just 7 days, according to the study abstract.

Acknowledging the historical harm caused by sole reliance on the measure for decisions in clinical practice, the AMA urges clinicians to incorporate other valid measures.

Nearly half of responding medical professionals said patients without T2D have asked for an Ozempic Rx and about 18% of them have provided one, avoiding significant backlash for a denial.

Compounded versions of semaglutide, often sold online, may contain salt versions of the molecule and are not evaluated by the FDA for safety or efficacy.

Your daily dose of clinical news you may have missed.

Efficacy of the daily pill met the standard now established by the once-weekly injection of 15% loss of baseline bodyweight in adults with overweight or obesity, says Novo Nordisk.

In a new guideline, the WHO recommends against the use of nonsugar sweeteners to control body weight or reduce the risk of noncommunicable diseases.

Dr Caroline Apovian reminds primary care clinicians who care for patients with obesity that diet and lifestyle counseling are essential for maximum results.

The dual GIP/GLP-1 receptor agonist was associated with a nearly 15% reduction in body weight in adults with overweight/obesity and without type 2 diabetes.